$Novo Nordisk AS(NVO.US)$Unitedhealth(UNH.US) insists that Novo Nordisk and UnitedHealth are wrongly sold off. While tech stocks are soaring, the pharmaceutical and biotech sectors continue to decline. In the long run, value will return. Novo Nordisk's products are fine, but its management is mediocre, and it's a non-U.S. company. This round of mis-selling is a good opportunity to buy in batches. Unfortunately, the third batch of the pyramid strategy order at 44.7 was not reached and could not be bought. Fortunately, long calls were bought as a supplement. UnitedHealth, as the largest private health insurance company in the U.S., is too big to fail. We hope it can adjust its course and embrace the new era. Based on the projected annual earnings per share of 16 yuan, the current price of 15.31 is already very attractive. Pyramid buying and waiting for the wind to come.